Risk factors for resistance to fluoroquinolones in nosocomial infections caused by Klebsiella pneumoniae and Escherichia coli
In recent years, the frequency of acquired resistance of microorganisms to fluoroquinolones has increased considerably. Resistance to this class of antibiotics increases significantly even in common nosocomial pathogens such as Klebsiella pneumoniae and Escherichia coli, in which the development of acquired resistance fluoroquinolones was considered unlikely. Since fluoroquinolones are currently one of the main classes of antibiotics for the treatment of nosocomial infections, identifying risk factors for resistance to these antimicrobials to maintain their effectiveness when used in clinical practice is d 'of particular importance.
To determine risk factors for resistance to fluoroquinolones in nosocomial infections caused by K. pneumoniae and E. coli, a case study was conducted by a team of scientists led by Dr. E. Lautenbach Control "in hospital patients. Between January 1998 and June 1999, 123 patients with nosocomial infections caused by K. pneumoniae and E. coli resistant to fluoroquinolones were included in the study. As a control group, 70 patients with nosocomial infections caused by strains of these microorganisms sensitive to fluoroquinolones were randomly selected.
The results of the study showed that the recent history of the use of antimicrobials in patients with a history of these diseases is an independent risk factor for resistance to fluoroquinolones in nosocomial infections caused by K. pneumoniae and E.coli odds ratio - SST = 5.25 and 95% confidence interval - CI = 1.81-15.26); stay in nursing hospitals (for example, nursing homes) (OS = 3.65 and 95% CI = 1.64–8.15); recent use of aminoglycoside antibiotics (OR = 8.86 and 95% CI = 1.71-45.99); advanced and senile age of the patients (OS = 1.03 and 95% CI = 1.01-1.06).
Additional studies are needed to investigate these risk factors and identify possible measures to inhibit the development of resistance to fluoroquinolones and to maintain the efficacy of this class of antibacterial drugs in the treatment of nosocomial infections caused by gram- common negatives, such as K.pneumoniae and E.coli.